PriceTargets.com logo

Crescent Biopharma - CBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.86
  • Forecasted Upside: 200.91%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 3 Strong Buy Ratings
$9.59 As of 01/30/2026 05:00 PM ET
▼ -0.56 (-5.52%)

This chart shows the closing price for CBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Crescent Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBIO

Analyst Price Target is $28.86
▲ +200.91% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Crescent Biopharma in the last 3 months. The average price target is $28.86, with a high forecast of $35.00 and a low forecast of $22.00. The average price target represents a 200.91% upside from the last price of $9.59.

This chart shows the closing price for CBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Crescent Biopharma. This rating has held steady since August 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/3/2026
  • 3 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 3 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/28/2026Piper SandlerInitiated CoverageOverweight$35.00
1/28/2026Piper SandlerInitiated CoverageStrong-Buy$35.00
1/21/2026GuggenheimInitiated CoverageBuy$35.00
1/21/2026GuggenheimInitiated CoverageBuy$35.00
12/29/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
12/22/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
12/15/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
12/8/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
12/4/2025Stifel NicolausSet Target$32.00
12/1/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
11/24/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
11/18/2025Weiss RatingsReiterated RatingSell (E-) ➝ Sell (E-)
11/12/2025Weiss RatingsInitiated CoverageSell (E-) ➝ Sell (E-)
8/27/2025HC WainwrightReiterated RatingBuy ➝ Buy$25.00
8/25/2025Jefferies Financial GroupInitiated CoverageBuy$26.00
8/11/2025HC WainwrightInitiated CoverageBuy$25.00
7/14/2025WedbushInitiated CoverageOutperform$27.00
6/25/2025Stifel NicolausInitiated CoverageBuy$28.00
6/20/2025TD CowenUpgradeStrong-Buy
6/18/2025Lifesci CapitalUpgradeStrong-Buy$22.00
11/12/2021JonestradingDowngradeBuy ➝ Hold
11/12/2021Piper SandlerLower TargetOverweight$1,600.00 ➝ $400.00
11/12/2021Raymond James FinancialDowngradeOutperform ➝ Market Perform
9/10/2021JonestradingReiterated RatingBuy$1,800.00
8/9/2021JonestradingInitiated CoverageBuy$1,800.00
8/6/2021Raymond James FinancialLower TargetOutperform$1,900.00 ➝ $1,800.00
7/20/2021Raymond James FinancialSet TargetBuy$431.00
7/1/2021Chardan CapitalReiterated RatingBuy
4/29/2021Raymond James FinancialBoost TargetOutperform$1,800.00 ➝ $1,900.00
3/4/2021Raymond James FinancialSet TargetOutperform$1,800.00
2/10/2021Piper SandlerInitiated CoverageOverweight$1,500.00
2/4/2021Raymond James FinancialLower TargetOutperform$2,000.00 ➝ $1,800.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025
  • 8 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/3/2026
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Crescent Biopharma logo
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $9.59
Low: $9.43
High: $11.21

50 Day Range

MA: $12.61
Low: $9.59
High: $15.31

52 Week Range

Now: $9.59
Low: $9.43
High: $37.00

Volume

198,338 shs

Average Volume

161,420 shs

Market Capitalization

$133.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Crescent Biopharma?

The following Wall Street research analysts have issued research reports on Crescent Biopharma in the last year: Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Piper Sandler, Stifel Nicolaus, TD Cowen, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for CBIO.

What is the current price target for Crescent Biopharma?

0 Wall Street analysts have set twelve-month price targets for Crescent Biopharma in the last year. Their average twelve-month price target is $28.86, suggesting a possible upside of 200.9%. Guggenheim has the highest price target set, predicting CBIO will reach $35.00 in the next twelve months. Lifesci Capital has the lowest price target set, forecasting a price of $22.00 for Crescent Biopharma in the next year.
View the latest price targets for CBIO.

What is the current consensus analyst rating for Crescent Biopharma?

Crescent Biopharma currently has 1 sell rating, 5 buy ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CBIO will outperform the market and that investors should add to their positions of Crescent Biopharma.
View the latest ratings for CBIO.

What other companies compete with Crescent Biopharma?

Other companies that are similar to Crescent Biopharma include Emergent Biosolutions, Lexicon Pharmaceuticals, Myriad Genetics, Vanda Pharmaceuticals and Verastem. Learn More about companies similar to Crescent Biopharma.

How do I contact Crescent Biopharma's investor relations team?

Crescent Biopharma's physical mailing address is P.O. BOX 65, MONROVIA, MD 21770, US. The biopharmaceutical company's listed phone number is 617-465-0586 and its investor relations email address is [email protected] . The official website for Crescent Biopharma is www.crescentbiopharma.com. Learn More about contacing Crescent Biopharma investor relations.